Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance

BACKGROUND Resmetirom received accelerated approval from the United States Food and Drug Administration (FDA) in March 2024 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH; formerly known as nonalcoholic steatohepatitis or NASH) with moderate to advanced liver fibrosis consistent with stages F2 to F3 fibrosis (F2-F3).1 The approval was based on findings from the MAESTRO-NASH clinical trial2 combined with safety data from the MAESTRO-NAFLD-1 trial.3 In the MAESTRO-NASH trial, treatment with resmetirom achieved the 2 primary endpoints of resolution of steatohepatitis without worsening of fibrosis (26%-30% compared with 10% for resmetirom and placebo, respectively) and improvement in…